ArticleBMC pulmonary medicine2026
Association between steatotic liver disease (MASLD, met-ALD, and ALD) with preserved ratio impaired spirometry: a population-based study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Inflammation-Metabolism Axis in Preserved Ratio Impaired Spirometry: Pathogenic Mechanisms and Translational Implications.Journal of inflammation research · 2026Review
- MASLD Exacerbates Chronic Low-dose PMIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreserved Ratio Impaired Spirometry (PRISm) is related to increased morbidity and mortality. Recently, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated alcohol-related liver disease (Met-ALD), and alcohol-associated liver disease (ALD) have been recognized as systemic metabolic disorders. The association between these novel liver disease categories and PRISm remains unclear.
methodsWe analyzed data from 23,414 adults aged ≥ 40 years from the 2010–2019 Korean National Health and Nutrition Examination Survey. Participants with obstructive lung patterns were excluded. MASLD, Met-ALD, and ALD were defined based on hepatic steatosis index, cardiometabolic criteria, and alcohol consumption. PRISm was defined as FEV₁/FVC ≥ 0.7 and FEV₁ <80% predicted. Complex sample logistic regression was used to examine associations, adjusting for sociodemographic, behavioral, and clinical variables. Subgroup analyses by sex and sensitivity analyses using AST-to-platelet index (APRI) for advanced fibrosis and lower limit of normal (LLN)-based criteria for PRISm were performed.
resultsAmong the study population, 3,182 had PRISm. MASLD, Met-ALD, and ALD were more prevalent in the PRISm group than in the normal spirometry group. In fully adjusted models, MASLD (OR 1.36; 95% CI, 1.19–1.55) and Met-ALD (OR 1.51; 95% CI, 1.14–2.01), and ALD (OR 2.38; 95% CI, 1.65–3.41) were associated with increased odds of PRISm. These associations were significant in males but not in females. Sensitivity analyses using LLN showed consistent results. Participants with advanced fibrosis (APRI ≥ 0.34) also had higher odds of PRISm in both sexes.
conclusionMASLD, Met-ALD, and ALD are associated with PRISm, particularly in men, suggesting a possible link between liver-based metabolic dysfunction and non-obstructive pulmonary impairment. These findings highlight the need for integrated approaches to managing metabolic liver disease and lung function decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.